x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DIA-0230809
| Product Information | |
|---|---|
| CAS No. | 136194-77-9 |
| Synonyms | PD406976 |
| Chemical Name | 5,6,7,13-Tetrahydro-13-methyl-5-oxo-12H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-12-propanenitrile |
| Formula | C24H18N4O |
| Molecular Weight | 377.42 |
| PubChem CID | 3501 |
| SMILES | C[N]1C2=C(C=CC=C2)C3=C1C4=C(C5=C3C(=O)NC5)C6=C(C=CC=C6)[N]4CCC#N |
| Target | PKC |
| Product Description | Go6976 is a potent PKC inhibitor with IC50 of 7.9 nM, 2.3 nM, and 6.2 nM for PKC (Rat brain), PKCα, and PKCβ1, respectively. Also a potent inhibitor of JAK2 and Flt3. |
| Format & Storage | |
|---|---|
| Purity | > 99% |
| Source | Synthetic |
| Shipping | Shipped on dry ice. |
| Storage | Powder: -20 °C, 3 years; 4 °C, 2 years In solvent: -80 °C, 6 months; -20 °C, 1 month |
| Solubility Overview | Soluble in DMSO |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
